Skip to main content
Fig. 5 | Diagnostic Pathology

Fig. 5

From: DNA damage response and repair gene mutations are associated with tumor mutational burden and outcomes to platinum-based chemotherapy/immunotherapy in advanced NSCLC patients

Fig. 5

Kaplan–Meier survival analysis for PFS and OS according to mutation status in BER pathway and FANCG gene. (A-D) Survival analysis of BER pathway mutations on the PFS and OS in all NSCLC patients receiving platinum-based chemotherapy/immunotherapy (A-B) and LUAD patients receiving platinum-based chemotherapy/immunotherapy (C-D). (E-H) Survival analysis of FANCG mutations on the PFS and OS in all NSCLC patients receiving platinum-based chemotherapy/immunotherapy (E-F) and LUAD patients receiving platinum-based chemotherapy/immunotherapy (G-H). PFS: progression-free survival, OS: overall survival

Back to article page

Diagnostic Pathology

ISSN: 1746-1596

Contact us